Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

Parse Biosciences Launches the Next Generation of its Immune Profiling Kits

June 10, 2026 at 08:00 AM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Updated kits deliver improved sensitivity and receptor recovery for single cell immune repertoire profiling at unprecedented scale

Parse Biosciences, the leading provider of scalable and accessible single cell sequencing solutions, today launched the next generation of its Evercode™ TCR and Evercode™ BCR kits, shipping to customers worldwide. The updated kits deliver a streamlined workflow, better whole transcriptome sequencing library efficiency, and improved performance, enabling researchers to resolve rare clonotypes and profile immune responses at unprecedented scale.

Immunology researchers are working to understand complex adaptive immune responses, but meaningful signals are often rare, transient, or difficult to capture across large, sample-limited studies. Parse's immune profiling portfolio combines scale, sensitivity, and fixation-first workflows with paired TCR or BCR and whole transcriptome profiling, helping researchers connect clonal identity to cell state across high-throughput immune studies.

Both Evercode TCR and Evercode BCR are now built on the same v4 chemistry that powers the latest Evercode Whole Transcriptome, unifying immune repertoire and transcriptomic studies on a single workflow. Evercode BCR v4 captures B cell receptor and whole transcriptome data from the same cell, with improved sensitivity for paired CDR3 detection and full-length heavy and light chain recovery, giving researchers a more complete view of clonal identity alongside cell state. Evercode TCR captures T cell receptor and whole transcriptome data from the same cell, and v4 preserves the sensitive alpha-beta CDR3 pairing for which the product is known.

"Paired whole transcriptome and immune repertoire data are foundational to understanding everything from autoimmunity to cancer immunotherapy response. By building Evercode TCR and BCR on v4 chemistry, we're giving researchers a meaningful boost in the quality of data they can generate, which we believe will accelerate discovery across the field," said Charlie Roco, PhD, Co-founder and Chief Technology Officer at Parse Biosciences.

Researchers interested in learning more about the updated versions of Evercode TCR and BCR can explore the following datasets on Parse’s website:

About Parse Biosciences

Parse Biosciences, a QIAGEN company, is a global life sciences company whose mission is to accelerate progress in human health and scientific research. Empowering researchers to perform single cell sequencing with unprecedented scale and ease, its pioneering approach has enabled groundbreaking discoveries in cancer treatment, tissue repair, stem cell therapy, kidney and liver disease, brain development, and the immune system.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260610248563/en/

"By building Evercode TCR and BCR on v4 chemistry, we're giving researchers a meaningful boost in the quality of data they can generate, which we believe will accelerate discovery across the field," said Charlie Roco, PhD, Co-founder of Parse Biosciences.

Contacts

Kaitie Kramer
kkramer@parsebiosciences.com | +1-858-504-0455

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Symbol

Price

Change (%)

AMZN

241.70

+3.36 (1.41%)

AAPL

294.38

+5.02 (1.73%)

AMD

540.88

-40.03 (-6.89%)

BAC

58.36

+1.38 (2.42%)

GOOG

357.89

+4.56 (1.29%)